Related Experiment Video
Updated: Jun 17, 2025
08:25
Detection of Cell-Free DNA in Blood Plasma Samples of Cancer Patients
Published on: September 9, 2020
11.0K
Prospects for liquid biopsy approaches in lymphomas
Esraa Jamal1,2, Edward Poynton1, Mohamed Elbogdady2
1Centre of Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Leukemia & Lymphoma
|August 10, 2024
Summary
Liquid biopsies using circulating tumor DNA (ctDNA) show promise for lymphoma diagnosis, monitoring, and relapse detection. Further standardization is needed for widespread clinical use.
Area of Science:
- Oncology
- Genetics
- Biomarkers
Background:
- Liquid biopsies offer a less invasive alternative to tissue biopsies for cancer diagnostics.
- Circulating tumor DNA (ctDNA) is a key analyte in liquid biopsies, particularly for hematologic malignancies like lymphoma.
Purpose of the Study:
- To review the clinical applications of ctDNA in various lymphoma types.
- To highlight ctDNA's role in diagnosis, disease monitoring, and relapse detection.
- To discuss advancements and challenges in ctDNA analysis for lymphoma.
Main Methods:
- Review of current literature on ctDNA in lymphoma.
- Exploration of next-generation sequencing (NGS) and machine learning applications.
- Analysis of ctDNA's utility in understanding tumor genetics and heterogeneity.
Main Results:
- ctDNA analysis provides insights into lymphoma tumor heterogeneity and genetic profiling.
- ctDNA aids in predicting treatment response and detecting relapse.
- Studies indicate ctDNA has prognostic value and can facilitate early detection.
Conclusions:
- ctDNA is a valuable tool for lymphoma management, offering potential for personalized treatment.
- Advancements in NGS and machine learning enhance ctDNA's clinical utility.
- Standardization of workflows is crucial for integrating ctDNA into routine clinical practice.
